Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers

An Open Label, Randomized, Single Dose, Crossover, Phase I Study to Evaluate the Pharmacokinetics and the Safety of D311 and D107 Compared to CKD-339 in Healthy Adult Volunteers

This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-339 in healthy volunteers.

Study Overview

• Status: Not yet recruiting
• Conditions: Hypertension
• Intervention / Treatment: Drug: CKD-339; Drug: D311, D107

Detailed Description

To 76 healthy subjects, following treatments, are administered dosing in each period and wash-out period is 14 days.

Pharmacokinetic blood samples are collected up to 72hrs. The pharmacokinetic characteristics and safety are assessed.

• Study Type: Interventional
• Enrollment (Estimated): 76
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Taegon Hong, M.D.; Phone Number: +82-2-2620-0251; Email: tghong@bumin.co.kr

Study Locations

• South Korea
  • Seoul, South Korea
    • Bumin Hospital
    • Contact: Taegon Hong, M.D.; Phone Number: +82-2-2620-0251; Email: tghong@bumin.co.kr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy adults between the age of 19 and 55 (inclusive) at the time of screening test.

2. Subjects with a body mass index(BMI) between 18 and 30 kg/m2(BMI = Weight(kg)/ Height(m)2)

   • Male subjects weighing at least 50 kg
   • Female subjects weighing at least 45 kg
3. Subjects who do not have clinically meaningful congenital or chronic diseases and who do not have medical examination results (such as electroencephalogram, electrocardiogram, chest and gastroscopy or gastrointestinal radiography, if necessary) during screening visits.
4. Subjects judged by investigators to be suitable for screening tests based on laboratory tests (e.g., blood tests, urine tests) and ECG, which were conducted according to the characteristics of the IP.
5. Subjects who voluntarily signed and dated the informed consent form after fully understanding its contents.

6. Subjects who had agreed to use medically appropriate contraceptive methods* to exclude the possibility of pregnancy from the first dose of the IP to 14 days after the last dose, and not to donate sperm or ovum.

   • contraceptive methods: Combination use of intrauterine device (IUD) or system (IUS), vasectomy, tubal ligation, tubal occlusion and barrier methods of contraception (male condoms, female condoms, cervical caps, contraceptive diaphragm, sponges, etc.) or the use of combined spermicide, involves the simultaneous use of two or more barrier methods.

Exclusion Criteria:

1. Subjects who have taken a drug metabolase-inducing and inhibiting drug such as barbitals within one month prior to the first dosing date or a drug that may interfere with this test within 10 days prior to the first dose of IP.
2. Subjects who had been administered investigational product from other clinical study or bioequivalence study within the 6 months prior to the first dose of IP.
3. Subjects who donated whole blood within 8 weeks, or blood components within 2 weeks prior to the first dose of IP.
4. Subjects who have a history of gastrointestinal resection that may affect the absorption of drugs.

5. Subjects with a history of regular alcohol consumption meeting any of the following criteria within 1 month prior to the first dose of IP.

   • Man: average alcohol consumption > 21 cups/weeks
   • Woman: average alcohol consumption > 14 cups/weeks

6. Patients with the following conditions

   • Patients who have a history of hypersensitivity to main or component of clinical trial drugs and other dihydropyridine drugs
   • Patients on angiotensin converting enzyme (ACE) inhibitor or not more than 36 hours after discontinuation of administration
   • Patients with a history of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor antagonists (ARB) administration
   • Patients with hereditary or idiopathic angioedema
   • Patients with severe liver failure, cirrhosis or biliary obstruction, bile congestion
   • Patients with diabetes or moderate to severe renal impairment (eGFR < 60mL/min/1.73m2) who have been co-administered with alliskyrene
   • Patients with primary aldosteronism
   • Shock patients (including cardiac shock)
   • Patients with severe aortic valve stenosis
   • Patients with unstable angina
   • Patients within one month of the onset of myocardial infarction
7. Subjects with a history of psychiatric disorders.
8. Subjects who are considered unsuitable for participation in this bioequivalence study by the Investigator (or delegated Sub-investigator) for reasons other than the inclusion and exclusion criteria listed above.
9. Female subjects who are pregnant, suspected of being pregnant, or breastfeeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sequence A(Reference-Test); Period 1: A single oral dose of 2 tablets under fasting condition(D311, D107), Period 2: A single oral dose of 1 tablet under fasting condition(CKD-339)	Drug: CKD-339; QD, PO; Other Names: Test; Drug: D311, D107; QD, PO; Other Names: Reference
Experimental: Sequence B(Test-Reference); Period 1: A single oral dose of 1 tablet under fasting condition(CKD-339), Period 2: A single oral dose of 2 tablets under fasting condition(D311, D107)	Drug: CKD-339; QD, PO; Other Names: Test; Drug: D311, D107; QD, PO; Other Names: Reference

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUCt of CKD-339	Area under the plasma CKD-339 concentration-time curve from 0 to t	From 0 to 72 hours postdose
Cmax of CKD-339	The maximum concentration of CKD-339 in plasma	From 0 to 72 hours postdose

Collaborators and Investigators

• Sponsor: Chong Kun Dang Pharmaceutical

Study record dates

Study Major Dates

• Study Start (Estimated): August 20, 2026
• Primary Completion (Estimated): October 6, 2026
• Study Completion (Estimated): October 12, 2026

Study Registration Dates

• First Submitted: July 28, 2026
• First Submitted That Met QC Criteria: July 31, 2026
• First Posted (Actual): August 6, 2026

Study Record Updates

• Last Update Posted (Actual): August 6, 2026
• Last Update Submitted That Met QC Criteria: July 31, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Hypertension
• Other Study ID Numbers: A164_01BE2511

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No